Phase 3 N=5,035 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Dyslipidemia
Primary: Number of Participants Who Experienced an Adverse Event — 2144; 2084 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=54 A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
Macular Edema
Primary: Number of Participants Experiencing at Least One Adverse Events (AEs) — 13; 7 Participants
Phase 3 N=245 Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 15.96; 17.71 mmHg — p=<0.00001
Phase 3 N=1,195 Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Hyperkalemia
Primary: Changes in Serum K+ Levels From Baseline — 0.029; 0.127 Milliequivalents Per Liter (mEq/l) — p=< 0.001
Phase 3 N=206 Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events (AEs) — 2.4 percentage of participants
Phase 3 N=25 Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
Heart Failure
Primary: Healthcare Utilization Costs — 2920.30; 7512.30 US Dollars — p=<0.0001
Phase 3 N=36 Bezafibrate Plus Berberine in Mixed Dyslipidemia
Mixed Dyslipidemia
Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L
Phase 3 N=1,650 Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With…
Phase 3 N=1,305 Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Primary: OS From Date of Randomization Until Death From Any Cause - Number of Events — 229; 304; 422; 350 Participants — p=<0.0001
Phase 3 N=643 GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
Alzheimer Disease
Primary: Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11) — 23.7; 23.4; 23.6; 26.6 score on a scale — p=<0.0455
Phase 3 N=189 L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects
Acute Lung Injury
Primary: A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use. — 3351.1; 3549.6 Minutes — p=0.4930
Phase 3 N=230 Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
Attention Deficit Hyperactivity Disorder · ADHD
Primary: Change in ADHD-RS-IV Total Score From Baseline (Visit 2) to the End of the Double-Blind Phase (Visit 3) — 9.3; 11.2; 12.3; 13.2 units on a scale — p=0.0046
Phase 3 N=210 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
Chronic Lymphocytic Leukemia (CLL)
Primary: Mean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality…
Phase 3 N=12 VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Niemann-Pick Disease, Type C
Primary: Parts A/B: Change From Baseline to Week 52 in 4-Item Composite Score of Niemann Pick Type C Severity Scale (NPC-SS) Score — 8.1; 8.8; -0.1; 0.0 score on a scale
Phase 3 N=40 The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Metabolic Syndrome
Primary: Flow Mediated Vasodilation — 9.5; 10.8; 10.5; 10.9 percentage of vasodilation